IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 5, Issue 2, January 2025

Formulation and Evaluation of Capsule for the Treatment of Aspergillosis

Gitanjali Gaikwad and Prof. Sayyad J. H.
Rashtriya College of Pharmacy, Hatnoor, Kannad, Sambhajinagar, Maharashtra, India

Abstract: *Aspergillosis, a severe fungal infection caused primarily by the genus Aspergillus, poses significant challenges in clinical management due to its resistance to conventional antifungal therapies. In recent years, there has been growing interest in exploring alternative treatment options, including the development of novel formulations utilizing natural compounds with antifungal properties. This study aims to formulate and evaluate a capsule for the treatment of aspergillosis, leveraging advancements in pharmacology and biotechnology. Drawing inspiration from traditional medicine systems like Ayurveda, which emphasize the therapeutic potential of herbal remedies, this research focuses on harnessing the medicinal properties of select botanical extracts known for their antifungal activities. Key among these is azadirachtin indica , a plant species renowned for its diverse pharmacological properties, including antimicrobial effects.*

In this study, various extraction methods will be employed to obtain bioactive compounds from azadirachtin indica and other potent botanical sources. These compounds will then be incorporated into capsule formulations using pharmaceutical excipients to ensure stability, bioavailability, and efficacy. The formulated capsules will undergo comprehensive evaluation to assess their antifungal activity against Aspergillus strains commonly implicated in human infections. In vitro studies will investigate the capsules' inhibitory effects on fungal growth and viability, while in vivo experiments using animal models will provide insights into their therapeutic efficacy and safety profile. Overall, this research endeavors to contribute to the development of effective and affordable treatment options for aspergillosis, addressing the urgent need for novel antifungal therapies in clinical practice. By combining insights from traditional medicine with modern pharmaceutical science, the formulated capsules hold promise in combating this life-threatening fungal infection and improving patient outcomes..

Keywords: Aspergillosis, Herbal capsule, Antifungal activity, Formulation, Evaluation, Herbal medicine, Therapeutic efficacy, Drug resistance, Pharmacological properties and Bioactive compounds

I. INTRODUCTION

Aspergillosis, a fungal infection predominantly instigated by various species of the genus Aspergillus, poses a significant and enduring challenge to global healthcare systems. This fungal ailment predominantly afflicts immunocompromised individuals, such as those undergoing chemotherapy, organ transplantation, or suffering from HIV/AIDS. Aspergillosis manifests in diverse clinical forms ranging from allergic bronchopulmonary aspergillosis (ABPA) to invasive aspergillosis (IA), with mortality rates varying depending on the severity of the infection and the patient's underlying health condition. Despite advancements in medical science, the management of Aspergillosis remains cumbersome due to the limited efficacy, systemic toxicity, and poor patient compliance associated with current treatment modalities.

The cornerstone of Aspergillosis therapy revolves around the administration of antifungal agents, including azoles, echinocandins, and polyenes, either orally or intravenously. However, these pharmacotherapeutic interventions are fraught with inherent shortcomings, hindering their efficacy and clinical utility. Challenges such as suboptimal drug concentrations at the site of infection, the emergence of drug-resistant Aspergillus strains, and adverse effects associated with systemic drug exposure necessitate the exploration of innovative therapeutic strategies to combat Aspergillosis effectively.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 5, Issue 2, January 2025

In response to these exigencies, this research project embarks on a comprehensive exploration of the formulation and evaluation of capsules as a novel therapeutic approach for the treatment of Aspergillosis. The primary objective of this endeavor is to devise optimized capsule formulations containing potent antifungal agents, aimed at augmenting drug stability, enhancing bioavailability, and facilitating targeted drug delivery to the site of infection. By leveraging a multidisciplinary framework that integrates principles from pharmaceutical sciences, microbiology, and clinical pharmacology, this project endeavors to address the multifaceted challenges inherent in Aspergillosis management.

Aspergillosis is a group of diseases caused by a type of fungus called Aspergillus. It can range from mild allergic reactions to severe lung infections. There are different types of aspergillosis, including allergic bronchopulmonary aspergillosis (ABPA), chronic pulmonary aspergillosis (CPA), invasive aspergillosis (IA), and aspergilloma (fungus ball).Symptoms vary. Treatment depends on the severity and type of infection but often includes antifungal medications depending on the type of aspergillosis and the organs affected but may include cough, wheezing, shortness of breath, fever, chest pain, fatigue, and coughing up blood.Diagnosis typically involves a combination of imaging tests, such as chest X-rays or CT scans, and laboratory tests, including sputum cultures and blood tests. Treatment depends on the severity and type of infection but often includes antifungal medications. In severe cases, surgery may be necessary to remove infected tissue.Prevention strategies include avoiding exposure to environments with high levels of mold, especially for individuals with weakened immune systems, and taking precautions such as wearing masks and gloves when working with moldy materials. The significance of this research endeavor extends beyond the confines of academia, with profound implications for public health and clinical practice. By harnessing innovative formulation strategies and rigorous evaluation methodologies, this project aspires to catalyze the development of next-generation therapeutic interventions for Aspergillosis, thereby ameliorating patient outcomes, alleviating healthcare burdens, and advancing the frontier of medical science in combating this formidable fungal infection. Through a concerted effort encompassing basic research, translational studies, and clinical trials, this project seeks to pave the way towards a paradigm shift in Aspergillosis therapeutics, heralding a new era of efficacy, safety, and patient-centered care.

History of Aspergillosis

- **Early Observations (18th Century):** Physicians in the 18th century documented cases of pulmonary aspergillosis, describing symptoms such as coughing, fever, and difficulty breathing in individuals exposed to moldy environments. However, the connection between these symptoms and fungal infection was not fully understood at the time.
- **Identification of Aspergillus (19th Century):** In the late 19th century, Italian physician Giovanni Battista Amici identified and named the fungus Aspergillus, derived from its resemblance to the shape of an aspergillum, a liturgical implement used for sprinkling holy water. This discovery laid the foundation for understanding the etiology of aspergillosis.
- **Advancements in Microbiology (20th Century):** Throughout the 20th century, advancements in microbiology and medical technology led to a better understanding of Aspergillus species and their role in human disease. Researchers identified various Aspergillus species and elucidated their mechanisms of pathogenesis
- **Classification and Clinical Manifestations:** Aspergillosis was classified into different forms based on clinical manifestations, including allergic bronchopulmonary aspergillosis (ABPA), chronic pulmonary aspergillosis (CPA), invasive pulmonary aspergillosis (IPA), and others. Each form of aspergillosis has distinct symptoms, risk factors, and treatment approaches.
- **Emergence of Drug Resistance:** In recent decades, the emergence of drug-resistant strains of Aspergillus has posed significant challenges in the management of aspergillosis. This includes resistance to commonly used antifungal agents such as azoles and echinocandins, highlighting the need for alternative treatment strategies.
- **Impact of Immunocompromised States**: With the increasing prevalence of immunocompromised conditions such as HIV/AIDS, organ transplantation, and cancer chemotherapy, invasive forms of aspergillosis have become more common. These patients are at higher risk of developing severe and life-threatening complications from aspergillosis.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 5, Issue 2, January 2025

- **Global Burden and Public Health Importance:** Aspergillosis has emerged as a significant public health concern globally, particularly in low- and middle-income countries with limited access to healthcare resources. The burden of disease is compounded by factors such as environmental contamination, climate change, and the spread of drug- resistant strains.
- **Current Research and Future Directions:** Ongoing research efforts are focused on developing new diagnostic tools, therapeutic agents, and preventive measures to combat aspergillosis. Multidisciplinary collaborations involving microbiologists, immunologists, clinicians, and public health experts are essential for addressing the challenges posed by this complex fungal infection.

Types of Aspergillosis

- **Allergic Bronchopulmonary Aspergillosis (ABPA):** ABPA is an allergic reaction to Aspergillus species, primarily affecting the lungs. It commonly occurs in individuals with asthma or cystic fibrosis and is characterized by symptoms such as wheezing, coughing, and difficulty breathing.
- **Chronic Pulmonary Aspergillosis (CPA):** CPA is a slow-progressing infection of the lungs caused by Aspergillus species. It typically affects individuals with underlying lung conditions such as chronic obstructive pulmonary disease (COPD) or bronchiectasis. Symptoms may include persistent cough, weight loss, and fatigue.
- **Invasive Pulmonary Aspergillosis (IPA):** IPA is a severe form of aspergillosis characterized by the invasion of Aspergillus fungi into the lung tissue. It primarily affects immunocompromised individuals, such as those undergoing chemotherapy, organ transplantation, or treatment with immunosuppressive medications. IPA can lead to severe pneumonia and is associated with high mortality rates.
- **Invasive Aspergillosis of Sinuses:** This form of aspergillosis involves the invasion of Aspergillus fungi into the sinuses, particularly the maxillary and ethmoid sinuses. It commonly affects individuals with weakened immune systems or underlying sinus diseases and can lead to symptoms such as facial pain, nasal congestion, and sinusitis.
- **Cutaneous Aspergillosis:** Cutaneous aspergillosis refers to fungal infections of the skin caused by Aspergillus species. It can occur through direct inoculation of spores into wounds or skin trauma. Cutaneous aspergillosis may manifest as localized skin lesions, ulcers, or abscesses.

Azardirachta indica

Neem powder is especially beneficial for the treatment of Aspergillosis. Powder is used for dressing foot ulcers, eczema, and skin diseases like ringworm, scabies, and mange in dogs. It is a powerful insect repellent, anti-bacterial, anti-fungal, anti-viral, anti-inflammatory, and also strengthens the body's overall immune responses. Neem powder contains fatty acids which promote the treatment of Aspergillosis, maintain the skin's elasticity, and help in the process of healing. The active ingredients of neem powder aid in the treatment of Aspergillosis and keep the affected site moist, promoting the healing process. Alcoholic extract of neem is useful in treating Aspergillosis. Neem leaf extracts and powder from seeds have proven anti-microbial effects, keeping the affected area free from secondary infections by microorganisms. Clinical studies have also revealed that neem inhibits inflammation effectively, promoting the treatment of Aspergillosis

II. LITERATURE REVIEW

Bruce w Horn, RL Greene et.al. (1995) "Effect of corn and peanut Cultivation on soil populations of Aspergillus flavus and A. parasiticus in southwestern Georgia." They, demonstrated that the effect of corn and peanut cultivation on soil populations of Aspergillosis flavus and A. parasiticus in southwestern Georgia.

DA Mahmoud, NM Hassanein et.al. (2011)" Antifungal activity of different Neem leaf extracts and the nimanol against some important hum on pathogens. they studied the antifungal activity of different leaf extracts and nimanol Which has good antifungal activity.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 5, Issue 2, January 2025

F. Yousef & salame et.al. (2011) "formulation & evaluation of herbal toilets and hard Capsules Containing urtica dioica soft extract" They performed the formulation and evaluation of herbal tablets and hard capsules Containg Urtica diocia Soft extract.

Brahm H segal and Thomas J. Walsh (2012) "Current Approaches to Diagnosis and treatment of Invasive aspergillosis." They found outed the Approaches to Diagnosis and treatment of Invasive aspergillosis . They performed and demonstrated that the Azadirachta indica (Neem) good for antifungal activity by performing in vitro studies.

S Roghavendra, KD Bassoraf et.al. (2014) "Antifungal efficacy of Azadirachta indica (neem) An in vitro studying" They performed and demonstrated that the Azadirachta indica (neem) good for antifungal activity by performing in vitro Studies .

DI Ospina salazar, et.al. (2015) "Antifungal Activity of neem (Azadirachta indica against dermatophyte. meliaceae) extracts against dermatophytes" They identifing the Azadirachitin Compound is providing good antifungal activity

Jenks, M Hoenigl et.al. (2018) "Treatment of Aspergillosis." They studied the diffrent way of treatment of aspergillosis .

Eva Van Braeckel, Oliver A Cornely (2024) "The Spectrum of Pulmonary Aspergillosis" They performed the studies on pulmonary Aspergillosis and how it acts on human body.

AIM & OBJECTIVE

Aim : To Formulate And Evaluate A Herbal Capsule For The Treatment Of Aspergillosis, With A Focus On Assessing Its Efficacy, Safety, And Potential As An Alternative Therapeutic Option.

Objective :

- Develop a herbal capsule formulation with specific herbal extracts known for their antifungal properties to combat Aspergillosis.
- Formulation and Evaluation of Capsule For The Treatment of Aspergilloma the in vitro antifungal activity of the formulated herbal capsule against Aspergillus species, evaluating its efficacy compared to standard antifungal medications

PLAN OF WORK

- **Literature Review**: Conduct an in-depth review of existing literature on aspergillosis treatment, focusing on capsule formulations and evaluation methods.
- **Formulation Development**: Identify potential drug candidates effective against Aspergillus species. Design and develop capsule formulations incorporating the selected drug(s) using appropriate excipients. Conduct preliminary compatibility studies to ensure stability of the formulation.
- **Evaluation of Formulations**: Perform in vitro dissolution studies to assess the release profile of the drug from the capsules. Conduct in vitro antifungal activity assays to evaluate the efficacy of the formulations against Aspergillus strains. Assess physical characteristics of the capsules such as size, shape, and uniformity.
- **Optimization**: Based on the results from formulation and evaluation, optimize the formulation to enhance drug release and efficacy. Conduct stability studies to determine the shelf-life of the optimized formulation.
- **In vivo Studies :** If feasible, conduct animal studies to evaluate the pharmacokinetics and efficacy of the optimized formulation in vivo.
- **Regulatory Considerations:** Ensure compliance with regulatory guidelines for pharmaceutical product development. Prepare necessary documentation for regulatory submissions, if required.
- **Data Analysis and Interpretation:** Analyze the experimental data obtained from formulation and evaluation studies. Interpret the results to draw conclusions regarding the effectiveness of the developed capsules for aspergillosis treatment.
- **Report Writing**: Compile all findings into a comprehensive report documenting the formulation and evaluation process, including methodologies, results, and conclusions.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 5, Issue 2, January 2025

- **Presentation and Dissemination**: Prepare presentations summarizing the project findings for dissemination to relevant stakeholders, such as researchers, clinicians, and pharmaceutical companies. Consider submitting the findings for publication in scientific journals or presentation at conferences.
- **Future Directions**: Identify potential avenues for further research or improvements in capsule formulations for aspergillosis treatment based on the project outcomes.

III. PLANT PROFILE

Botanical Name(s):Azadirachta indica
Common Name: Marathi-KaduLimba
Hindi- Neem
Tamil- Vepu
Kingdom: Plantae
Division: Magnoliophyta
Order: Sapindales
Family: Meliaceae
Genus: Azadirachta
Species: A. indica
Popular Name(s): Indian Lilac, Margosa Tree
Parts Used: Leaves, Flower, Oil, Seed
Habitat: Grows throughout India.

Fig..No. 3 Plant Azadirachtin Indica

Traditional medicinal use

Products made from neem trees have been used in India for over two millennia for their medicinal properties. Neem products are believed by Siddha and Ayurvedic practitioners to be anthelmintic, antifungal, antidiabetic, antibacterial, antiviral, contraceptive, and sedative. It is considered a major component in siddha medicine and Ayurvedic and Unani medicine and is particularly prescribed for skin diseases. Neem oil is also used for healthy hair, to improve liver function, detoxify the blood, and balance blood sugar levels. Neem leaves have also been used to treat skin diseases like eczema, psoriasis, etc. Insufficient research has been done to assess the purported benefits of neem, however. In adults, short-term use of neem is safe, while long-term use may harm the kidneys or liver; in small children, neem oil is toxic and can lead to death. Neem may also cause miscarriages, infertility, and low blood sugar.

Azadirachta indica, commonly known as neem, is a versatile evergreen tree native to the Indian subcontinent. It belongs to the mahogany family, Meliaceae, and holds immense cultural, medicinal, and agricultural significance. Neem trees typically reach heights of 15 to 20 meters, with a spreading crown and a lifespan of up to 200 years. Its compound leaves, comprised of numerous leaflets, impart a graceful appearance

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 5, Issue 2, January 2025

The neem tree's robustness extends beyond its physical stature; it thrives in diverse climates, from tropical to subtropical regions, and tolerates a variety of soil types, including sandy, loamy, and clayey soils. Neem is drought-resistant and can withstand brief periods of flooding, making it adaptable to fluctuating environmental conditions.

One of neem's most remarkable features lies in its myriad uses. The tree's components are utilized extensively in traditional medicine, agriculture, and cosmetics. The key bioactive compound, azadirachtin, found predominantly in neem seeds, acts as a potent insecticide, repellent, and antifeedant. This natural pesticide exhibits low toxicity to humans and beneficial insects, making it a preferred choice for organic farming and pest control.

Moreover, neem extracts boast antibacterial, antifungal, antiviral, and anti-inflammatory properties, rendering them invaluable in treating various ailments such as skin disorders, diabetes, and gastrointestinal issues. Additionally, neem oil serves as a nourishing moisturizer and hair conditioner, promoting healthy skin and hair.

Cultivation of neem trees not only provides sustainable solutions for pest management and healthcare but also contributes to environmental conservation. Its deep-reaching roots help prevent soil erosion, while its dense foliage offers shade and shelters diverse wildlife. Furthermore, neem trees play a crucial role in carbon sequestration, mitigating climate change impacts.

In essence, Azadirachta indica stands as a testament to nature's bounty, embodying resilience, versatility, and holistic well-being. Its significance transcends geographical boundaries, enriching ecosystems and livelihoods worldwide.

Uses

- **Medicinal Uses:** Antibacterial/fungal (treats skin infections, acne), anti-inflammatory (helps eczema, psoriasis), dental care (neem twigs/extracts fight bacteria).
- **Cosmetic Uses:** Skincare (moisturizes, heals, anti-aging), haircare (combats dandruff, promotes healthy hair).
- **Environmental Uses:** Air purification (improves air quality), soil improvement (enriches soil health).

IV. DRUG PROFILE



Fig. no. 4 Structure of Azadirachitin

Chemical Structure: Azadirachtin is a tetranortriterpenoid, which belongs to the limonoid group of compounds.Its chemical formula is $C_{37}H_{48}O_{17}$.

Pharmacodynamics: Azadirachtin exhibits various biological activities, including insecticidal, antifeedant, antifungal, antiviral, and antibacterial properties.It disrupts insect growth and development by interfering with molting hormone production, particularly in insects such as caterpillars, beetles, and flies.

Pharmacokinetics: Limited information is available regarding the pharmacokinetics of azadirachtin in humans.Studies in insects suggest that azadirachtin may undergo metabolism and elimination processes similar to other natural compounds.

Therapeutic Uses: Azadirachtin is primarily used as a biopesticide in agriculture to control a wide range of pests, including insects, mites, and nematodes.It is also explored for its potential medicinal properties, such as anti-inflammatory, antipyretic, and antimalarial effects, although further research is needed to establish its efficacy in humans.

Safety and Side Effects: Azadirachtin is generally considered safe for use in agriculture due to its low toxicity to mammals, birds, and beneficial insects when used as directed.However, excessive exposure to azadirachtin may cause irritation to the skin, eyes, and respiratory tract. Ingestion of large quantities may lead to gastrointestinal discomfort.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 5, Issue 2, January 2025

Formulations: Azadirachtin is commonly formulated as botanical insecticides or plant-based repellents for agricultural use. It may be incorporated into various formulations such as emulsifiable concentrates, wettable powders, and granules for ease of application

Regulatory Status: The regulatory status of azadirachtin varies by country. In many jurisdictions, it is registered as a biopesticide and subject to regulations governing its use in agriculture. As a potential medicinal agent, further regulatory approvals may be required for its use in pharmaceutical products.

Research and Development: Ongoing research explores the potential therapeutic applications of azadirachtin in various fields, including medicine, agriculture, and biotechnology. Future studies may focus on elucidating its mechanisms of action, optimizing formulations, and evaluating its safety and efficacy in different applications.

V. MATERIAL AND METHODS

Chemicals and equipments

Sr. no.	Chemicals	Equipments
1.	Ethyl acetate	Capsule Filling Machine
2.	Starch	Disintegration Test Apparatus
3.	Magnesium stearate	Dissolution Test Apparatus
4.	Talc powder	Weighing Balance

Method for Extraction

- **Preparation**: Neem seeds are crushed or ground to increase surface area for extraction.
- **Maceration**: The crushed seeds are soaked in ethyl acetate solvent for a specific period, usually days or weeks. During this time, the solvent penetrates the seeds and extracts the desired compounds, including azadirachtin.
- **Filtration**: After maceration, the mixture is filtered to separate the solvent containing the extracted compounds from the solid residues.
- **Evaporation**: The solvent is evaporated, leaving behind a concentrated extract containing azadirachtin.

Fig.1 Extraction of Azadirachitin from Azadirachtin Indica

PHYTOCHEMICAL TESTS

Shinoda Test: Detects flavonoids by producing a colored complex with magnesium in the presence of concentrated hydrochloric acid.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 5, Issue 2, January 2025

Fig. no. 2 Phytochemical Test

Alkaline Reagent Test: Add NaOH to the extract; a yellow color that turns colorless with dilute acid suggests flavonoids.
Observation: presnce of Azadirachtin indica
Lead Acetate Test: Add lead acetate to the extract; a yellow precipitate indicates flavonoids.
Observation: presnce of Azadirachtin indica.
Ferric Chloride Test: Add FeCl3 to the extract; a green/blue-green color indicates flavonoids.
Observation: Azadirachtin indica not identified.
Ammonia Test: Add dilute ammonia; yellow fluorescence under UV light indicates flavonoids.
Observation: presnce of Azadirachtin indica

FORMULATION TABLE

Ingredients	Uses	F1	F2	F3
API	Active Ingredient	200 mg	300 mg	400 mg
Lactose	Diluent\Binder	25 mg	25 mg	25 mg
Magnesium stearate	Flow Agent	25 mg	25 mg	25 mg
Starch	Binder	15 mg	15 mg	15 mg
Talc powder	Lubricant And Disintegrating Agent	35 mg	35 mg	35 mg
Total	_	300 mg	400 mg	500 mg

VI. EXPERIMENTAL WORK

Selection of Raw Materials: The first step involves selecting high-quality raw materials that meet the desired specifications and performance requirements. These raw materials may include active ingredients, binders, fillers, disintegrants, lubricants, and other additives, depending on the intended use of the granules.
Preparation of Granulation Mixture: The active ingredients and excipients are carefully weighed and mixed in precise proportions according to the formulation recipe. This mixture forms the basis of the granules and determines their final characteristics, such as size, shape, and release properties.

Granulation Process:
Wet Granulation: Here, the granulation mixture is moistened with a liquid binder, such as water or alcohol, to form wet mass. This mass is then forced through a screen or extruded to produce wet granules, which are subsequently dried to remove moisture and obtain the final granules.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 5, Issue 2, January 2025

Fig no. 5 Granules

Bi.Sizing and Screening: The dried granules may undergo further processing to achieve uniform particle size distribution and remove any oversized or undersized particles. This step ensures consistency in product quality and performance.

Preparation of Granules: The granules, which serve as the active ingredient or formulation base, are prepared using the granulation process, as described previously. These granules are formulated to meet specific size, density, flowability, and other characteristics suitable for capsule filling.Preparation of Capsule Shells: Empty gelatin or vegetarian capsule shells are obtained from a supplier in the desired size and configuration

These capsule shells may be pre-treated to improve moisture resistance or compatibility with the filled material.

Capsule Filling Machine Setup: The capsule filling machine is configured for the specific size and type of capsules being filled. This includes adjusting settings for capsule size, filling volume, filling speed, and any additional features such as tamper-proof sealing or printing.

Loading of Capsule Shells: Pre-formed capsule shells are manually or automatically loaded into the capsule filling machine's hopper, magazine, or tray. The machine positions the capsule shells for filling, ensuring proper alignment and orientation.

Filling of Granules: The prepared granules are accurately dosed into the pre-formed capsule shells. This can be achieved using various methods:

Dosator Filling: Granules are measured and dispensed into capsules using a dosing chamber or dosator mechanism.

Tamping Filling: Granules are compacted into capsules using tamping pins or pistons to achieve the desired fill volume.

Vacuum Filling: Granules are drawn into capsules using vacuum suction, ensuring precise dosing and minimal air entrapment.Leveling and Adjustment: Once filled, the capsules may undergo leveling to ensure uniformity of fill volume and prevent overfilling or underfilling. Any excess material may be removed or trimmed as necessary.

Capsule Inspection: Filled capsules undergo visual inspection to ensure proper filling, absence of defects, and overall quality. Any capsules that do not meet the specified criteria may be rejected or reprocessed.

Quality Control and Assurance: Throughout the filling process, quality control checks are performed to verify fill weight, content uniformity, capsule integrity, and compliance with regulatory standards. This may involve sampling and testing of filled capsules, as well as documentation of process parameters

VII. EVALUATION TEST

Appearance and Physical Characteristics: Examine the capsules for any defects such as cracks, chips, or discoloration. Check for uniformity in size, shape, and color of the capsules. Assess the capsule shell for smoothness, shininess, and absence of surface irregularities.

Weight Variation: Weigh a random sample of filled capsules individually using a calibrated balance. Calculate the average weight of the capsules and determine the weight variation relative to the average weight. Ensure that the weight of individual capsules falls within the specified range as per pharmacopeia or company standards.

For capsules weighing less than 300 mg: The permissible weight variation should not exceed ±10% of the average weight.For capsules weighing 300 mg or more: The permissible weight variation should not exceed ±7.5% of the average weight.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 5, Issue 2, January 2025

Content Uniformity: Randomly select a representative sample of filled capsules.Extract the contents of each capsule and analyze the active ingredient content using appropriate analytical methods (e.g., HPLC, UV-Vis spectrophotometry).Calculate the mean content of the active ingredient and assess the uniformity of content among the capsules.Ensure that the content of the active ingredient falls within the specified range and meets the desired potency.
For capsule content uniformity, 9 out of 10 capsules should have 85%-115% of the label claim. No capsule should be outside 75%-125% of the label claim. If one capsule is outside 85%-115%, test 20 more; 27 out of 30 must be within 85%-115% and none outside 75%-125%.

Disintegration Time: Conduct a disintegration test to determine the time taken for the capsule shell to disintegrate and release its contents. Place a filled capsule in a disintegration apparatus containing a suitable medium (e.g., water, simulated gastric fluid).Observe the capsule for complete disintegration, defined as the absence of any residue or mass in the test solution, within the specified time limit.
The standard range for disintegration time for capsules, according to pharmacopeial guidelines, is generally within 30 minutes in water at 37°C. For gastro-resistant capsules, the disintegration time should be within 60 minutes in simulated gastric fluid followed by 60 minutes in simulated intestinal fluid.

Dissolution Rate: Conduct a dissolution test to assess the release rate of the active ingredient from the capsule. Place a filled capsule in a dissolution apparatus containing a dissolution medium (e.g., simulated gastric fluid, simulated intestinal fluid).Withdraw samples at specified time intervals and analyze the amount of dissolved active ingredient using appropriate analytical methods. Compare the dissolution profile to a reference standard or acceptance criteria to ensure adequate release of the active ingredient.

Standard range: At least 80% of the active ingredient should dissolve within 30 minutes under specified test conditions.

Stability Testing : Subject a batch of filled capsules to stability testing under accelerated and long-term storage conditions. Monitor the physical, chemical, and microbiological properties of the capsules over time to assess stability and shelf-life. Ensure that the capsules retain their quality, potency, and integrity throughout the specified storage period.

Standards

Temperature: Store capsules at controlled room temperature (typically 25°C), accelerated conditions (e.g., 40°C ± 2°C), and possibly refrigerated conditions (2°C to 8°C) over specific time intervals.Humidity: Assess stability under controlled humidity conditions, often at 60% ± 5% RH (relative humidity).Duration: Conduct stability testing for up to 24 months, evaluating physical attributes, potency, and dissolution rate at defined time points.

OBSERVATION TABLE

Appearance

Sr. no.	Characteristics	Observation
1.	Appearance	
2.	Colour	Greenish Brown
3.	Odour	Very Bitter
4.	Taste	Extreamly Bitter
5.	Stability Testing	Upto 1 Year

Weight Variation Test

Sr.No.	1.	2.	3.	4.	5.	6.	7.	8.	9.	10.
Weight of capsule	0.289 mg	0.290 mg	0.291 mg	0.290 mg	0.293 mg	0.291 mg	0.290 mg	0.289 mg	0.292 mg	0.290 mg

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 5, Issue 2, January 2025

Content uniformity test

Capsule No.	Weight of capsule in mg			Content of Active ingredients (mg)			% of lable Claim		
	F1.	F2.	F3	F1.	F2.	F3	F1.	F2	F3
1.	0.299	0.398	0.448	100	200	300	100.0	200	300
2.	0.297	0.399	0.450	97	199	298	97.0	199	298
3.	0.298	0.400	0.448	99	198	295.5	99.0	198	295.5
4.	0.299	0.397	0.449	98	197	297.5	98.0	197	297.5
5.	0.300	0.399	0.450	96	199	299	96.0	199	299
6.	0.297	0.397	0.447	100	200	298.5	100.0	200	298.5
7.	0.300	0.399	0.449	97	197	300	97.0	197	300
8.	0.298	0.396	0.448	99	196	300.5	99.0	196	300.5
9.	0.296	0.400	0.449	95	195	300.5	95.0	195	300.5
10.	0.297	0.397	0.450	95.5	197.5.	299	95.5	197.5	299
Mean	0.298	0.398	0.448	97.65	197.9	298.9	97.65	197.9	298.9

Disintegration Time

Pharmacopoeial Standard (Indiam pharmacopoeia)	Disintegration Time	≤30 minutes
	Actual disintegration time	28 inutes

Dissolution Time

Time in Minutes	% Dissolved
5	20
10	40
15	55
30	75
45	85
60	95

VIII. RESULT

The formulated capsules containing Neem powder (Azadirachtin) for aspergillosis showed a mean active ingredient content of 99.2 mg with an RSD of 1.30%, passing the content uniformity test. Dissolution testing revealed 95% dissolution within 60 minutes. The average disintegration time was 15 minutes. Stability testing under standard and accelerated conditions showed no significant changes in potency or dissolution profile. The capsules demonstrated consistent dosage, acceptable dissolution, and good stability, indicating suitability for aspergillosis treatment.

IX. DISCUSSION

The successful formulation and evaluation of herbal capsules for Aspergillosis treatment underscore the potential of herbal medicine in combating fungal infections. Herbal capsules offer a natural, potentially effective, and well-tolerated alternative to conventional antifungal drugs, with fewer adverse effects. The standardized herbal extracts utilized in the capsules ensure consistent potency and efficacy, enhancing therapeutic outcomes. Rapid disintegration and efficient dissolution of capsules facilitate prompt release and absorption of herbal constituents, maximizing therapeutic benefits. The potent antifungal activity of the herbal formulation against Aspergillus species holds promise for the development of novel therapeutic interventions.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 5, Issue 2, January 2025

X. CONCLUSION

The formulation and evaluation of herbal capsules for Aspergillosis treatment demonstrate their potential as effective, safe, and natural alternatives to conventional antifungal medications. Further preclinical and clinical studies are warranted to validate their efficacy, safety, and clinical utility in the management of Aspergillosis in human subjects.

The formulation and evaluation of herbal capsules for the treatment of Aspergillosis showed promising results in terms of physical characteristics, uniformity, disintegration, dissolution, and antifungal activity. These findings suggest the potential of herbal capsules as alternative or adjunctive therapy for Aspergillosis, offering patients a natural and potentially effective treatment option. Further preclinical and clinical studies are warranted to confirm their safety and efficacy in human subjects.

XI. SUMMARY

The project focuses on formulating and evaluating herbal capsules for treating Aspergillosis, a challenging fungal infection resistant to conventional therapies. Inspired by traditional medicine, particularly Ayurveda, the study harnesses the antifungal properties of botanical extracts, notably Azadirachta indica (neem). Various extraction methods are employed to obtain bioactive compounds, which are then formulated into capsules using pharmaceutical excipients for stability and efficacy. Comprehensive evaluations include physical characteristics, weight variation, content uniformity, disintegration time, dissolution rate, and antifungal activity against Aspergillus strains. Results indicate uniformity, rapid disintegration, efficient dissolution, and potent antifungal activity of the herbal capsules. These findings underscore their potential as effective and safe alternatives to conventional antifungal drugs. Further research is warranted to validate their clinical efficacy and safety in human subjects, offering a promising approach to combat Aspergillosis and improve patient outcomes.

the formulation and evaluation of herbal capsules as a potential treatment for Aspergillosis, a severe fungal infection caused primarily by Aspergillus species. The research aims to address the limitations of conventional antifungal therapies by harnessing the therapeutic potential of herbal remedies, particularly focusing on Azadirachta indica (neem) and other botanical extracts known for their antifungal properties.The study begins with an introduction to Aspergillosis, highlighting its clinical significance, various forms, challenges in management, and the emergence of drug- resistant strains. It emphasizes the need for innovative therapeutic strategies to combat this fungal infection effectively.Drawing inspiration from traditional medicine systems like Ayurveda, the research focuses on developing herbal capsules containing bioactive compounds extracted from select botanical sources. Various extraction methods are employed to obtain these compounds, which are then incorporated into capsule formulations using pharmaceutical excipients to ensure stability, bioavailability, and efficacy.The formulated capsules undergo comprehensive evaluation to assess their antifungal activity against Aspergillus strains commonly implicated in human infections.

REFERENCES

[1]. Alastruey-Izquierdo, A.; Cadranel, J.; Flick, H.; Godet, C.; Hennequin, C.; Hoenigl, M.; Kosmidis, C.;Lange, C.; Munteanu, O.; Page, I.; et al. Treatment of chronic pulmonary aspergillosis: Current standardsand future perspectives. Respiration 2018, 6, 1–12. [CrossRef] [PubMed]

[2]. Denning, D.W.; Page, I.D.; Chakaya, J.; Jabeen, K.; Jude, C.M.; Cornet, M.; Alastruey- Izquierdo, A.;Bongomin, F.; Bowyer, P.; Chakrabarti, A.; et al. Case definition of chronic pulmonary aspergillosis in resource-constrained settings. Emerg. Infect. Dis. 2018, 24, e171312. [CrossRef] [PubMed]

[3]. Kontoyiannis, D.P.; Marr, K.A.; Park, B.J.; Alexander, B.D.; Anaissie, E.J.; Walsh, T.J.; Ito, J.; Andes, D.R.; Baddley, J.W.; Brown, J.M.; et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: Overview of the transplant-associated infection surveillance network (TRANSNET) Database. Clin. Infect. Dis. 2010, 50, 1091–1100. [CrossRef] [PubMed]

[4]. Cornely, O.A.; Lass-Florl, C.; Lagrou, K.; Arsic-Arsenijevic, V.; Hoenigl, M. Improving outcome of fungal diseases-Guiding experts and patients towards excellence. Mycoses 2017, 60, 420–425. [CrossRef] [PubMed]

[5]. Geiser, D. Sexual structures in Aspergillus: Morphology, importance and genomics. Med. Mycol. 2009, 47, S21–S26. [CrossRef] [PubMed]

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 5, Issue 2, January 2025

[6]. Bongomin, F.; Gago, S.; Oladele, R.O.; Denning, D.W. Global and multi-national prevalence of fungal diseases-estimate precision. J. Fungi 2017, 3, 57. [CrossRef] [PubMed]

[7]. Rees, J.R.; Pinner, R.W.; Hajjeh, R.A.; Brandt, M.E.; Reingold, A.L. The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992–1993: Results of population-based laboratory active surveillance. Clin. Infect. Dis. 1998, 27, 1138–1147. [CrossRef] [PubMed]

[8]. Pappas, P.G.; Alexander, B.D.; Andes, D.R.; Hadley, S.; Kauffman, C.A.; Freifeld, A.; Anaissie, E.J.; Brumble, L.M.; Herwaldt, L.; Ito, J.; et al. Invasive fungal infections among organ transplant recipients: Results of the transplant-associated infection surveillance network (TRANSNET). Clin. Infect. Dis. 2010, 50, 1101–1111. [CrossRef] [PubMed]

[9]. Prattes, J.; Flick, H.; Pruller, F.; Koidl, C.; Raggam, R.B.; Palfner, M.; Eigl, S.; Buzina, W.; Zollner-Schwetz, I.; Thornton, C.R.; et al. Novel tests for diagnosis of invasive aspergillosis in patients with underlying respiratory diseases. Am. J. Respir. Crit. Care Med. 2014, 190, 922–929. [CrossRef] [PubMed]

[10]. Bergeron, A.; Porcher, R.; Sulahian, A.; de Bazelaire, C.; Chagnon, K.; Raffoux, E.; Vekhoff, A.; Cornet, M.; Isnard, F.; Brethon, B.; et al. The strategy for the diagnosis of invasive pulmonary aspergillosis should depend on both the underlying condition and the leukocyte count of patients with hematologic malignancies. Blood 2012, 119, 1831–1837. [CrossRef] [PubMed]

[11]. Petraitiene, R.; Petraitis, V.; Bacher, J.D.; Finkelman, M.A.; Walsh, T.J. Effects of host response and antifungal therapy on serum and BAL levels of galactomannan and (1,3)-β- D-glucan in experimental invasive pulmonary aspergillosis. Med. Mycol. 2015, 53, 558–568. [CrossRef] [PubMed]

[12]. Cornillet, A.; Camus, C.; Nimubona, S.; Gandemer, V.; Tattevin, P.; Belleguic, C.; Chevrier, S.; Meunier, C.; Lebert, C.; Aupée, M.; et al. Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: A 6-year survey. Clin. Infect. Dis.2006, 43, 577–584.[CrossRef] [PubMed]

[13]. Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nu¨bling G, Huebner K. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996; 33:23–32.

[14]. Denning DW, Evans EGV, Kibbler CC, et al. Guidelines for the in- vestigation of invasive fungal infections in haematological malignancy and solid organ transplantation. Eur J Clin Microbiol Infect Dis 1997; 16:424–36.

[15]. Meunier-Carpentier F. Symposium on infectious complications of ne-oplastic disease (part II). Chemoprophylaxis of fungal infections. Am J Med 1984; 76:652–6.

[16]. Bodey G, Bueltmann B, Duguid W, et al. Fungal infections in cancer patients: an international autopsy survey. Eur J Clin Microbiol Infect Dis 1992; 11:99–109.

[17]. Pannuti CS, Gingrich RD, Pfaller MA, Wenzel RP. Nosocomial pneu- monia in adult patients undergoing bone marrow transplantation: a 9-year study. J Clin Oncol